After-market trading session, Pulmatrix Inc. (NASDAQ: PULM) shares increases by 6.32 percent to $1.01. Pulmatrix stock fell -5.94% to $0.95 on Friday. PULM stock volume stayed at 1.3 million shares, which was less than the average daily volume of 1.95 million shares for the past 50 days. Last year, PULM stock fell -31.16%, and in the last week, it has moved down by -4.52%.
PULM stock has lost -32.62% over the last three months and -9.52% over the last six months. Additional information pertaining to PULM includes a current market capitalization of $56.80 million and its outstanding shares stood at 36.16 million.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Recent developments:
Pulmatrix develops inhaled therapies, developed using Pulmatrix’s patented iSPERSE technology, to address serious pulmonary diseases. There are several treatments PULM has in its pipeline, including treatments for serious lung diseases such as allergic bronchopulmonary aspergillosis (“ABPA”) and chronic obstructive pulmonary disease (“COPD”), as well as for neurological conditions.
Read More
Pulmatrix held a webinar last month on Friday, April 23, 2021 that covered the topic of PUR3100—Pulmatrix’s orally inhaled dihydroergotamine (DHE) therapy for acute migraines.
- Key opinion leaders including Stewart Tepper, MD, F.A.H.S., Geisel School of Medicine at Dartmouth, and Stephen Silberstein M.D., F.A.C.P., Thomas Jefferson University, presented on the webinar.
- Tepper spoke about how healthcare has evolved and unmet medical needs in treating patients with acute migraine.
- A new generation of DHE therapies is currently in the work, and Dr. Silberstein discussed the possibilities.
What’s next?
Pulmatrix (PULM) CEO, Ted Raad, also provided a corporate overview, including the focus of PUR3100, a dry powder synthesis of DHE to treat acute migraines. PULM’s PUR3100 is currently in preclinical trials as a migraine orally-inhaled therapy with Phase I and Phase II results expected by 2022.